FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2683915501> ?p ?o ?g. }

• W2683915501 endingPage "26723" @default.
• W2683915501 startingPage "26711" @default.
• W2683915501 abstract "// Jatinder K. Lamba 1 , Xueyuan Cao 2 , Susana C. Raimondi 3 , Roya Rafiee 1 , James R. Downing 3 , Lei Shi 2 , Tanja Gruber 4 , Raul C. Ribeiro 4 , Jeffrey E. Rubnitz 4 and Stanley B. Pounds 2 1 Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA 2 Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA 3 Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA 4 Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA Correspondence to: Jatinder K. Lamba, email: jlamba@cop.ufl.edu Keywords: AML; methylation; pediatrics; leukemia Received: February 16, 2018      Accepted: May 10, 2018      Published: June 01, 2018 ABSTRACT Acute myeloid leukemia (AML) may be an epigenetically-driven malignancy because it harbors fewer genomic mutations than other cancers. In recent studies of AML in adults, DNA methylation patterns associate with clinical risk groups and prognosis. However, thorough evaluations of methylation in pediatric AML have not been done. Therefore, we performed an integrated analysis (IA) of the methylome and transcriptome with clinical outcome in 151 pediatric patients from the multi-center AML02 clinical trial discovery cohort. Intriguingly, reduced methylation and increased expression of DNMT3B was associated with worse clinical outcomes (IA p ≤ 10 −5 ; q ≤ 0.002). In particular, greater DNMT3B expression associated with worse minimal residual disease (MRD; p < 10 −5 ; q = 0.01), a greater rate of relapse or resistant disease (RR) ( p = 0.00006; q = 0.06), and event-free survival (EFS; p = 0.00003; q = 0.04). Also, greater DNMT3B expression associated with greater genome-wide methylation burden (GWMB; R = 0.39; p = 10 −6 ) and greater GWMB associated with worse clinical outcomes (IA p < 10 −5 ). In an independent validation cohort of 132 similarly treated AAML0531 clinical trial patients, greater DNMT3B expression associated with greater GWMB, worse MRD, worse RR, and worse EFS (all p < 0.03); also, greater GWMB associated with worse MRD ( p = 0.004) and EFS ( p = 0.037). These results indicate that DNMT3B and GWMB may have a central role in the development and prognosis of pediatric AML." @default.
• W2683915501 created "2017-06-30" @default.
• W2683915501 creator A5003784173 @default.
• W2683915501 creator A5006746068 @default.
• W2683915501 creator A5012776569 @default.
• W2683915501 creator A5015143631 @default.
• W2683915501 creator A5028885623 @default.
• W2683915501 creator A5064611054 @default.
• W2683915501 creator A5066681200 @default.
• W2683915501 creator A5077113159 @default.
• W2683915501 creator A5082712798 @default.
• W2683915501 creator A5086250633 @default.
• W2683915501 date "2018-06-01" @default.
• W2683915501 modified "2023-10-17" @default.
• W2683915501 title "Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia" @default.
• W2683915501 cites W1419799953 @default.
• W2683915501 cites W1978788671 @default.
• W2683915501 cites W1983241335 @default.
• W2683915501 cites W1985292554 @default.
• W2683915501 cites W1990303725 @default.
• W2683915501 cites W1990763586 @default.
• W2683915501 cites W1998993441 @default.
• W2683915501 cites W2008420899 @default.
• W2683915501 cites W2014945558 @default.
• W2683915501 cites W2028152601 @default.
• W2683915501 cites W2039704444 @default.
• W2683915501 cites W2040835684 @default.
• W2683915501 cites W2043038685 @default.
• W2683915501 cites W2049266282 @default.
• W2683915501 cites W2055642036 @default.
• W2683915501 cites W2059981122 @default.
• W2683915501 cites W2060446375 @default.
• W2683915501 cites W2079497260 @default.
• W2683915501 cites W2079944042 @default.
• W2683915501 cites W2088967199 @default.
• W2683915501 cites W2097149753 @default.
• W2683915501 cites W2114366647 @default.
• W2683915501 cites W2117087916 @default.
• W2683915501 cites W2118250079 @default.
• W2683915501 cites W2124758034 @default.
• W2683915501 cites W2128919238 @default.
• W2683915501 cites W2129984982 @default.
• W2683915501 cites W2139278981 @default.
• W2683915501 cites W2146887040 @default.
• W2683915501 cites W2151528379 @default.
• W2683915501 cites W2152656267 @default.
• W2683915501 cites W2161930777 @default.
• W2683915501 cites W2164892300 @default.
• W2683915501 cites W2167033277 @default.
• W2683915501 cites W2167301808 @default.
• W2683915501 cites W2169923083 @default.
• W2683915501 cites W2208333084 @default.
• W2683915501 cites W2222013644 @default.
• W2683915501 cites W2255637773 @default.
• W2683915501 cites W2322005850 @default.
• W2683915501 cites W2337848504 @default.
• W2683915501 cites W2344387265 @default.
• W2683915501 cites W2509517672 @default.
• W2683915501 cites W2528784069 @default.
• W2683915501 cites W2560908657 @default.
• W2683915501 cites W2584687784 @default.
• W2683915501 cites W2754864362 @default.
• W2683915501 cites W2791754076 @default.
• W2683915501 cites W2792521257 @default.
• W2683915501 doi "https://doi.org/10.18632/oncotarget.25475" @default.
• W2683915501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6084389" @default.
• W2683915501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30101002" @default.
• W2683915501 hasPublicationYear "2018" @default.
• W2683915501 type Work @default.
• W2683915501 sameAs 2683915501 @default.
• W2683915501 citedByCount "25" @default.
• W2683915501 countsByYear W26839155012019 @default.
• W2683915501 countsByYear W26839155012020 @default.
• W2683915501 countsByYear W26839155012021 @default.
• W2683915501 countsByYear W26839155012022 @default.
• W2683915501 countsByYear W26839155012023 @default.
• W2683915501 crossrefType "journal-article" @default.
• W2683915501 hasAuthorship W2683915501A5003784173 @default.
• W2683915501 hasAuthorship W2683915501A5006746068 @default.
• W2683915501 hasAuthorship W2683915501A5012776569 @default.
• W2683915501 hasAuthorship W2683915501A5015143631 @default.
• W2683915501 hasAuthorship W2683915501A5028885623 @default.
• W2683915501 hasAuthorship W2683915501A5064611054 @default.
• W2683915501 hasAuthorship W2683915501A5066681200 @default.
• W2683915501 hasAuthorship W2683915501A5077113159 @default.
• W2683915501 hasAuthorship W2683915501A5082712798 @default.
• W2683915501 hasAuthorship W2683915501A5086250633 @default.
• W2683915501 hasBestOaLocation W26839155011 @default.
• W2683915501 hasConcept C104317684 @default.
• W2683915501 hasConcept C126322002 @default.
• W2683915501 hasConcept C143998085 @default.
• W2683915501 hasConcept C150194340 @default.
• W2683915501 hasConcept C187212893 @default.
• W2683915501 hasConcept C190727270 @default.
• W2683915501 hasConcept C2778729363 @default.
• W2683915501 hasConcept C2778987988 @default.
• W2683915501 hasConcept C41091548 @default.
• W2683915501 hasConcept C45091340 @default.

• next